Role of a cluster of long noncoding RNA transcripts in protecting the heart from pathological hypertrophy
AssigneeIndiana University Research and Technology Corporation
InventorChing-Pin Chang
Life of this patent
Estimating the term…
Abstract
Nucleic acids encoding modified myosin heavy-chain-associated RNA transcripts are provided. The modified myosin heavy-chain-associated RNA transcripts belongs to a cluster of long noncoding RNAs (lncRNA) and bind to chromatin remodeler Brg1 to inhibit Brg1's genomic targeting and gene regulation function. The modified myosin heavy-chain-associated RNA transcripts expressed in an individual inhibit Brg1's gene regulation function and protect the heart of the individual from myopathy and failure. One of the modified heavy-chain-associated RNAs is a 400 base pair fragment segmented from a natural 779 base pair sequence of Mhrt (Mhrt779) and has the same cardioprotective effects as the Mhrt779.
Claims32
A composition comprising a nucleic acid encoding a modified myosin heavy-chain-associated RNA transcript, wherein the modified myosin heavy-chain-associated RNA transcript inhibits Brg1's genomic targeting and gene regulation function in a subject to whom the composition is administered,
- wherein the modified myosin heavy-chain-associated RNA transcript comprises SEQ ID NO:
- 2.
A composition comprising a nucleic acid encoding a modified myosin heavy-chain-associated RNA transcript, wherein the modified myosin heavy-chain-associated RNA transcript inhibits Brg1's genomic targeting and gene regulation function in a subject to whom the composition is administered,
- wherein the modified myosin heavy-chain-associated RNA transcript comprises SEQ ID NO:
- 4.
A non-human organism carrying a transgene comprising a promoter and a nucleic acid encoding a modified myosin heavy-chain-associated RNA transcript,
- wherein the promoter regulates an expression of the nucleic acid to produce the modified myosin heavy-chain-associated RNA transcript in the organism, and
- wherein the modified myosin heavy-chain-associated RNA transcript inhibits Brg1's genomic targeting and gene regulation function in the organism;
- and
- wherein the modified myosin heavy-chain-associated RNA transcript is selected from the group consisting of:
- SEQ ID NO:
- 2 and SEQ ID NO:
- 4.
A method comprising:
- administering to a subject a composition comprising a nucleic acid encoding a modified myosin heavy-chain-associated RNA transcript to express the modified myosin heavy-chain-associated RNA transcript in the subject,
- wherein the modified myosin heavy-chain-associated RNA transcript inhibits Brg1's genomic targeting and gene regulation function in the subject;
- and
- wherein the modified myosin heavy-chain-associated RNA transcript is selected from the group consisting of:
- SEQ ID NO:
- 2 and SEQ ID NO:
- 4.
A treatment delivery apparatus comprising a device and at least one dosage of a composition contained in the device,
- wherein the composition comprises a nucleic acid encoding a modified myosin heavy-chain-associated RNA transcript,
- wherein the modified myosin heavy-chain-associated RNA transcript inhibits Brg1's genomic targeting and gene regulation function in a subject to whom the composition is administered;
- and
- wherein the modified myosin heavy-chain-associated RNA transcript is selected from the group consisting of:
- SEQ ID NO:
- 2 and SEQ ID NO:
- 4.
A method comprising:
- administering to a subject a composition comprising a modified myosin heavy-chain-associated RNA transcript;
- wherein the modified myosin heavy-chain-associated RNA transcript inhibits Brg1's genomic targeting and gene regulation function in the subject;
- and
- wherein the modified myosin heavy-chain-associated RNA transcript is selected from the group consisting of:
- SEQ ID NO:
- 2 and SEQ ID NO:
- 4.
Dependencies are inferred from the claim text.